A federal prosecutor has charged David Blech, a leading biotech financier in the early 1990s, with a single criminal count of securities fraud.

The "criminal information," which is the equivalent of an indictment but does not require the consent of a grand jury, was filed last week in the U.S. District Court for the Southern District of New York.